Published in

Springer Nature [academic journals on nature.com], Pharmacogenomics Journal, 2(17), p. 109-111, 2016

DOI: 10.1038/tpj.2016.73

Links

Tools

Export citation

Search in Google Scholar

Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene

Journal article published in 2016 by Apolonia Novillo Villajos, Alicia Romero Lorca, María Gaibar Alonso, Margarita Rubio Alonso ORCID, Ana Fernández Santander
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Tamoxifen (TAM) has been widely used to treat estrogen receptor (ER)-positive breast cancer, and has led to reduction of 50% in the annual recurrence rate and 30% in breast cancer mortality after 5 years of treatment.1 The prodrug TAM is a selective ER modulator that antagonizes ERs in cancer cells. However, compared with its two active metabolites 4-hydroxy-TAM (4-OH-TAM) and endoxifen, it is a relatively weak antiestrogen. ; SIN FINANCIACIÓN ; 3.784 JCR (2015) Q1, 52/255 Pharmacology & pharmacy; Q2, 47/166, Genetics & heredity ; UEM